Cheap Antidepressant Shows Promise Treating Early COVID-19

Fluvoxamine, a drug used for 30 years to treat OCD and depression, may also reduce inflammation and lower the risk of COVID hospitalization. A study involving 1500 COVID patients from Canada, the US, and Brazil showed that those who took fluvoxamine had a 33% reduction in hospitalizations compared to those who received a placebo.

What is the primary benefit of fluvoxamine in the context of COVID-19?

• It acts as a vaccine.

• It prevents COVID-19 infection.

• It lowers the risk of hospitalization.

• It cures COVID-19 completely.

For how many years has fluvoxamine been used to treat mental health conditions?

• 10 years

• 20 years

• 30 years

• 40 years

What additional property of fluvoxamine is highlighted by researchers?

• It boosts immunity.

• It enhances memory.

• It increases energy levels.

• It reduces inflammation.

Which countries were involved in the clinical trial of fluvoxamine for COVID-19?

• Canada, US, and Brazil

• UK, India, and Australia

• China, Japan, and South Korea

• Germany, France, and Italy

By what percentage did fluvoxamine reduce hospitalizations in the study?

• 75%

• 33%

• 25%

• 50%